MPZL3: A Drug Target / Disease Biomarker (G196264)

Target Name: MPZL3

NCBI ID: G196264

MPZL3

MPZL3: A Drug Target / Disease Biomarker

MPZL3, also known as MENinH, is a protein that is expressed in the brain and is known to play a role in the development and progression of multiple sclerosis (MS). The study of MPZL3 and its potential as a drug target has gained significant attention in recent years, and there is a growing body of research that suggests that it may be a promising candidate for MS treatments.

Multiple sclerosis is a chronic and unpredictable disease that affects the central nervous system and can cause a range of symptoms, including muscle weakness, vision problems, and fatigue. It is estimated that over 40 million people in the world have MS, and the number of new cases is expected to reach 450,000 by 2026. Currently, there are only a few approved MS medications that can slow down the progression of the disease and provide relief from symptoms.

MPZL3 is a protein that is expressed in the brain and is known to be involved in the immune response. It is a part of theMPZL gene family, which has also been implicated in the development of MS. Studies have shown that people with MS have lower levels of MPZL3 than healthy people. Additionally, research has suggested that manipulating MPZL3 levels may be a promising way to treat MS.

One of the key reasons why MPZL3 is being studied as a potential MS treatment is its ability to suppress the immune system response. MS is an autoimmune disease, and the immune system mistakenly attacks the body's own cells, including the brain, leading to the development and progression of the disease. By suppressing the immune system response, MPZL3 may be able to reduce the damage caused by MS and slow down the progression of the disease.

Another potential MS treatment that is being investigated using MPZL3 is its ability to repair damaged tissue. MS is known to cause damage to the myelin sheath that surrounds nerve cells, leading to the loss of function and the development of symptoms. MPZL3 has been shown to promote the growth and repair of damaged tissue in animal models of MS. This may suggest that it could be used to treat MS by promoting the repair of damaged tissue in the brain.

In addition to its potential as a MS treatment, MPZL3 is also being studied as a potential biomarker. The immune system response to MPZL3 may be a useful indicator of the severity of MS and could be used as a biomarker to monitor disease progression. Additionally, the levels of MPZL3 have been shown to be lower in people with MS compared to healthy people, which could be used as a biomarker to predict the risk of MS.

While there is still much to be learned about the potential of MPZL3 as a MS treatment, studies have shown that it has the potential to be a valuable tool in the treatment of this disease. Further research is needed to fully understand the effects of MPZL3 on MS and to develop safe and effective treatments.

Protein Name: Myelin Protein Zero Like 3

Functions: Mediates homophilic cell-cell adhesion

The "MPZL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPZL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets